Mayur M Amonkar
4PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Mar 20, 2026
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.Danmeng Huang, Ying Zhang, Riddhi A Babel
|May 23, 2023
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis.Lauren A Abderhalden, Ping Wu, Mayur M Amonkar
|Mar 25, 2022
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC.He Jin, Mayur Amonkar, Raquel Aguiar-Ibáñez
|Feb 21, 2022
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.Raquel Aguiar-Ibáñez, Chloë Hardern, Frank van Hees
Pageof 1
